Vaultree Achieves Google Cloud Ready - AlloyDB Designation
29.3.2023 16:00:00 EEST | Business Wire | Press release
Vaultree, the Data-In-Use Encryption leader, today announced that it has successfully achieved Google Cloud Ready - AlloyDB designation for AlloyDB for PostgreSQL, Google Cloud’s newest fully managed PostgreSQL-compatible database service for most demanding enterprise database workloads.
This market-expanding milestone follows Vaultree’s successful $12.8 million series A funding round, selection as the only Irish recipient of the European Innovation Council (EIC) grant and the appointment of renowned tech industry veteran Rinki Sethi to its executive board of directors.
Google Cloud Ready - AlloyDB is a new designation for the solutions of Google Cloud’s technology partners that integrate with AlloyDB. These partners have closely collaborated with Google Cloud to add support for AlloyDB into their solutions and tune their existing functionality for optimal outcomes. This designation recognizes the partner solutions that have met a core set of functional requirements and been validated in collaboration with Google Cloud engineering teams.
“Achieving the Google Cloud Ready - AlloyDB designation demonstrates that Vaultree’s data encryption in use capabilities have been validated by Google Cloud to integrate with AlloyDB to provide an excellent experience for customers,” said Ritika Suri, Director, Technology Partnerships at Google Cloud.
By earning this designation, Vaultree has proven its product has met a core set of functional and interoperability requirements when integrating with AlloyDB and refined documentation for ease of onboarding by the companies’ mutual customers. This designation enables customers to discover and have confidence that the Vaultree products they use today work well with AlloyDB and save time evaluating them.
As part of the program, Vaultree enjoys more opportunities to collaborate closely with Google Cloud partner engineering and AlloyDB teams to develop joint roadmaps.
Google Cloud’s ecosystem is designed to support industry-focused digital transformation. With this partnership, Vaultree enables customers to rely on end-to-end solutions through a reliable, fast and seamless integration of the most advanced encryption product on the market to rid themselves of the danger of plaintext data exposure.
“Breaches or leaks will continue to happen, no matter how many tools are in the first line of defense, but the second line of defense – encryption – has been neglected for decades because data still has to be decrypted in order to be worked with,” said Tilo Weigandt, COO and co-founder of Vaultree. “Our goal is to end that with our product and help enterprises to not just be compliant but secure and leave the worries behind.”
Vaultree with Google Cloud’s AlloyDB for PostgreSQL fulfills this goal, allowing customers to choose what to encrypt, and manage their own keys with zero learning and changes to the existing query languages, data structure, architecture, network topology or policies/permissions — all with minimal performance loss in the cloud.
“We are paving the way to a new era of cloud-based data protection by designing and offering the world’s first always-encrypted, Data-In-Use solution with unparalleled performance and simplicity, powered by Vaultree with Google’s AlloyDB for PostgreSQL,” said Ryan Lasmaili, CEO and co-founder of Vaultree. “Partnering with Google Cloud brings us reliability, flexibility and freedom to innovate and engage with a key player in an ever-changing industry to create the best data privacy solutions for enterprises of any kind, driving security and profitability, and accelerating digital transformation.”
To learn more about Vaultree’s expertise with AlloyDB, visit. To learn more about Google Cloud Ready - AlloyDB and its benefits, visit.
About Vaultree
Vaultree has developed the world’s first Fully Functional Data-in-Use Encryption solution that solves the industry’s fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare/pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale, without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree’s Data-In-Use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005299/en/
Contact information
Matt Culbertson
prforvaultree@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom